Rapt Therapeutics Inc.
RAPT Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
Summary
RAPT Therapeutics, Inc. announced its participation in the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company will present its drug development programs, including its novel next-generation omalizumab bio-better antibody, ozureprubart (RPT904), which is in Phase 2b clinical trial for food allergy and Phase 2 clinical trial for chronic spontaneous urticaria (CSU). RAPT also provided an update on its pipeline and financial position, indicating a cash runway projected through multiple clinical milestones. A copy of the Company's presentation materials for the JPM Conference is attached hereto as Exhibit 99.1.
Profitelligence Alerts
Get alerts for RAPT
Be first to know when Rapt Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Rapt Therapeutics Inc.
Rapt Therapeutics Inc. is a biotechnology firm focused on the discovery, development, and commercialization of oral small molecule therapies for oncology and inflammatory diseases. Its primary mission is to create novel treatments by harnessing its proprietary drug discovery platform, which targets key pathways responsible for the progression of these complex conditions. Rapt Therapeutics is notably advancing its development of selective inhibitors for immune checkpoint inhibitors within the broader cancer treatment landscape, potentially enhancing the efficacy of existing therapies. The company's pipeline includes multiple drug candidates tailored for specific types of cancer and chronic inflammatory disorders, underscoring its commitment to addressing unmet medical needs. By concentrating efforts on innovative approaches that modulate immune and inflammatory responses, Rapt Therapeutics plays a significant role in shaping the future of precision medicine in the biopharmaceutical industry. Founded in 2015 and leveraging advanced scientific insights, Rapt Therapeutics represents an important component of the biotech sector's efforts to push boundaries in disease treatment and improve patient outcomes.
Official SEC Documents
Advertisement